Sabarep (YP001) / York Pharma - LARVOL DELTA

A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD (ASH 2018) - P1; "Treatment response and overall survival rates are encouraging compared to previously published outcomes. The Cohort B primary evaluation period is expected to be completed by September 2018, and progression to a Phase II trial in this clinically challenging disease will then be considered."

P1 data • Biosimilar • Graft versus Host Disease • Hematological Disorders • Immunology • Neutropenia • Transplantation